Sharechat Logo

Healthscope's NZ pathology shares efficiencies with DHBs, stalling earnings growth

Tuesday 21st August 2018

Text too small?

Healthscope's New Zealand pathology business gave up earnings growth as it shared operating efficiencies with district health boards through the re-contracting process. 

The New Zealand lab testing division reported a 1 percent decline in revenue to A$240.2 million in the year ended June 30 and a 2.7 percent dip in operating earnings before interest, tax depreciation and amortisation to A$58.1 million. In NZ dollar terms, revenue rose 1.6 percent and earnings 2.5 percent, slowing from the unit's outperformance in 2017. 

"Revenue growth has moderated by the sharing of operational efficiencies with district health boards through re-contracting, combined with no new DHB contract work," the company said in its annual report. "The priority for Healthscope in New Zealand is maintaining strong relationships with the DHBs by delivering high-quality services and superior operational efficiencies."

The pathology business is willing to share "some of the long-term" gains with the DHBs to "strengthen existing relationships". Healthscope operates under the Labtests, Southern Community Laboratories, and Northland Pathology brands in New Zealand, and provides veterinary services through Gribbles Veterinary. 

Healthscope said the Gribbles Vet unit posted a "good performance" for revenue and margins "on the back of expanded services nationwide". 

Group profit fell 19 percent to A$89.4 million due to the cost of hospital closures and onerous lease provisions, while revenue increased 3.7 percent to A$2.34 billion. 

The Melbourne-based company completed a strategic review of its A$1 billion Australian hospital portfolio and plans to set up an unlisted property trust to house those assets, leasing them back to Healthscope. 

The ASX-listed shares slipped 0.2 percent to A$2.165. 

(BusinessDesk)

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MARKET CLOSE: NZ shares gain; a2 hits new record, F&P climbs on patent deal
NZ dollar eases against Aussie on strong jobs data
KiwiSaver funds face unrealised capital gains tax on NZ and Aussie shares
Planning changes need to speed renewables development - Meridian
A guide to the Tax Working Group's 'other' recommendations
MYOB adds 57% more subscribers in 2018 but total online customers still lag Xero's
Investors fear chilling effect as former IRD boss opposes capital gains proposals
Stuff 1H earnings slide but Nine still optimistic of finding buyer
NZ Post achieves first-half revenue growth for the first time since 2015
TeamTalk affirms annual earnings guidance as rising costs dent first-half profit

IRG See IRG research reports